SCHEMBL27207908

SCHEMBL27207908

CC12COC(CO)(C1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19871923 0.70 EPHX1 (0.39) —
SCHEMBL19748065 0.70 — —
SCHEMBL22585266 0.70 EPHX1 (0.30) —
SCHEMBL22585247 0.70 EPHX1 (0.30) —
SCHEMBL15334701 0.69 EPHX1 (0.42) —
SCHEMBL20934668 0.67 ASGR1 (0.30) —
SCHEMBL27089050 0.67 — —
SCHEMBL26967130 0.67 — —
SCHEMBL25433101 0.65 — —
SCHEMBL3810403 0.64 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 — — US disclosed
US-20240287064-A1 TRICYCLIC COMPOUND USED AS GPR84 ANTAGONIST Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2024-08-29 — — US disclosed
EP-4361151-A1 TRICYCLIC COMPOUND USED AS GPR84 ANTAGONIST Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2024-05-01 — — EP disclosed
Send feedback